Table 4.
Patients were classified into five groups according the preferential myosin loss, i.e., the M:A ratio. Differences in EDX and clinical parameters between the five groups were investigated using a one-way ANOVA. Value are means (or medians when stated) ± SD.
| 0≤ M:A < 0.5 | 0.5≤ M: < 1.0 | 1.0≤ M:A < 1.5 | 1.5 ≤ M:A < 1.7M:A≥ | 1.7 < myoact | ANOVA | |
|---|---|---|---|---|---|---|
| Age (yrs.) | 60.9± 10.8 | 63.3± 17.6 | 62.0± 11.9 | 61.2± 16.3 | 63.4± 10.3 | |
| Height (cm) | 170.0± 8.1 | 171.0± 11.6 | 174.2± 9.7 | 171.7± 9.1 | 174.9± 6.7 | |
| Disease duration when examined (d) | 26.0± 21.2 | 29.4± 18.1 | 24.5± 12.2 | 29.3± 20.8 | 25.9±12.1 | |
| Spont. EMG activity | 1.8± 1.0 | 2.0± 1.3 | 2.1± 1.3 | 1.9± 1.0 | 2.2±0.9 | |
| EMG findings | 0.9± 0.9 | 1.1± 1.4 | 1.1± 1.4 | 0.9± 1.3 | 1.2± 1.6 | |
| mCMAP (mV) | 2.5± 1.7 | 4.0± 3.8 | 9.3± 6.9 | 5.8± 5.3 | 8.7± 4.4 | p < 0.01 |
| nCMAP (mV) | 2.6± 1.7 | 3.7± 3.6 | 6.0± 6.0 | 5.5± 4.3 | 6.7± 2.1 | |
| mn-ratio | 1.2± 0.4 | 1.0± 0.8 | 0.7± 0.5 | 1.2± 0.6 | 0.9± 0.3 | |
| Refractory period (ms) | 14.7± 8.2 | 11.0± 6.9 | 9.5± 6.5 | 9.5± 6.2 | 3.0± 2.8 | |
| Signal duration (ms) | 34.2± 13.4 | 27.2± 16.1 | 22.0± 17.2 | 24.4± 17.9 | 22.0± 6.0 | |
| CMAP index | −6.4± 2.8 | −6.4± 3.0 | −6.8± 4.6 | −5.3± 3.6 | −5.7± 3.1 | |
| MCV index | −2.1± 2.4 | −2.9± 3.8 | −3.1± 3.8 | −2.5± 3.2 | −3.7± 3.4 | |
| SNAP index | −1.6± 2.1 | −1.3± 2.6 | −1.9± 2.1 | 2.9± 20.3 | −2.0± 3.3 | |
| SCV index | 0.3± 1.4 | 0.2± 1.7 | −0.3± 1.6 | 0.1± 1.4 | −0.2± 2.1 |